Introduction
============

Digestive system neoplasms (DSNs) are the leading cause of cancer-related death worldwide, and cause 3,056,412 deaths in 2018, which accounts for 32% of all cancer deaths worldwide.[@b1-dddt-13-183]--[@b3-dddt-13-183] This category comprises colorectal cancer, gastric cancer, liver cancer, esophageal cancer, and pancreatic cancer, which are the fourth, sixth, seventh, ninth, and fourteenth most common cancers, respectively.[@b1-dddt-13-183] Despite improvements in diagnostic and therapeutic methods in the past decades,[@b4-dddt-13-183] the prognosis of DSNs is still poor, because they are mostly diagnosed at advanced stages, which may be accompanied by extensive invasion and distant metastasis.[@b4-dddt-13-183]--[@b6-dddt-13-183] Therefore, effective therapeutic approaches should be developed.

In recent years, traditional Chinese medicine has been more widely used as auxiliary treatment in tumor therapy and has shown promising therapeutic effects in many clinical studies.[@b7-dddt-13-183]--[@b9-dddt-13-183] Sodium cantharidinate/vitamin B6 (SC/B6) is a combination of sodium cantharidinate (SC) and vitamin B6, and has the pharmacologic characteristics of both.[@b7-dddt-13-183],[@b8-dddt-13-183] SC is a derivative of cantharidin, which is extracted from the body of meloidae insects such as *Mylabris phalerata pallas* and *Mylabris cichorii linnaeus*.[@b10-dddt-13-183] SC preserves the unique anticancer activity of cantharidin and has lower toxicity and fewer adverse effects.[@b7-dddt-13-183],[@b10-dddt-13-183] Its combination with vitamin B6 can even further lower the side effects.[@b7-dddt-13-183] In recent years, SC has been used as a safe auxiliary antitumor drug for malignancies such as gastric cancer, liver cancer, and non-small-cell lung cancer.[@b7-dddt-13-183]--[@b9-dddt-13-183],[@b11-dddt-13-183] Tao et al[@b12-dddt-13-183] indicated that SC induces HepG2 cells to undergo apoptosis through the LC3 autophagy pathway. Liang et al[@b13-dddt-13-183] showed that SC can inhibit tumor growth by downregulating vascular endothelial growth factor expression and blocking tumor angiogenesis. In addition, SC can also have an anticancer effect by blocking progression through the cell cycle, inhibiting invasion/metastasis, and improving the immunity of cancer patients.[@b14-dddt-13-183]--[@b18-dddt-13-183]

Several clinical studies[@b8-dddt-13-183],[@b19-dddt-13-183]--[@b41-dddt-13-183] have revealed the prominent therapeutic effects of SC/B6 and conventional medical treatment (CMT, including chemotherapy, symptomatic, and supporting therapy) for advanced DSNs but clinical efficacy and safety have not been systematically evaluated. In this study, we performed a meta-analysis to evaluate the efficacy and safety of SC/B6 for DSN treatment, with a comparison between SC/B6 and CMT combined therapy and CMT alone, in order to provide scientific reference for the design of future clinical trials.

Materials and methods
=====================

Search strategy and selection criteria
--------------------------------------

Publications were searched across the Cochrane Library, Embase, Pubmed, Web of Science, Chinese Scientific Journal Database (VIP), China National Knowledge Infrastructure, and Wanfang databases, using the search terms "sodium cantharidinate" or "disodium cantharidinate" and "vitamin B6" combined with "gastric cancer" or "colorectal cancer" or "gastrointestinal cancer" or "liver cancer" or "esophageal cancer" or "pancreatic cancer" or "digestive system neoplasms" without restriction on the language. The retrieval was initiated in May 2018 and updated in August 2018.

All of the clinical trials brought into this analysis were randomized controlled trials with reference to advanced DSNs, in which patients in the experimental groups were treated by SC/B6 and CMT combined therapy, and patients in the control groups were treated by CMT alone.

Data extraction and quality assessment
--------------------------------------

Literature screening and data extraction were carried out by two independent investigators (Meirong Liu and Chunhong Xu) and verified by a third reviewer (Yingying Sun). All included studies were summarized as follows: first author name, year of publication, study location, Karnofsky Performance Score (KPS), number of cases, patient ages, study parameter type, treatment regimen and enrollment period, and administration route and dosage of SC/B6. The quality of the included trials was evaluated as described in the Cochrane Handbook.[@b42-dddt-13-183]

Outcome definition
------------------

Clinical responses, including therapeutic effects, quality of life (QoL), and adverse events, were analyzed. Therapeutic effects were evaluated by overall survival (OS) rate, complete response (CR) rate, partial response (PR) rate, stable disease (SD) rate, progressive disease (PD) rate, overall response rate (ORR, ORR = CR + PR), and disease control rate (DCR = CR + PR + SD). OS was defined as the length of time from the start of treatment to death from any cause; QoL was assessed using KPS scales and the European Organization for Research and Treatment of Cancer core quality-of-life questionnaire. The QoL improvement rate (QIR) was defined as the improvement in QoL after treatment. Adverse events, including leukopenia, nausea and vomiting, gastrointestinal side effects, hepatotoxicity, nephrotoxicity, diarrhea, thrombocytopenia, transaminase disorder, myelosuppression, hand-foot syndrome, oral mucositis, anorexia, and anemia, were also assessed.

Statistical analysis
--------------------

Review Manager 5.3 (Nordic Cochran Centre, Copenhagen, Denmark) and Stata 13.0 (Stata Corp., College Station, TX, USA) were the main statistical analysis tools in this study. *P*\<0.05 indicated statistically significant differences. Cochran's Q test was used to determine heterogeneity among studies,[@b43-dddt-13-183] and publication bias was analyzed by Begg's and Egger's regression asymmetry tests and presented by funnel plots.[@b44-dddt-13-183] *I*^2^\<50% or *P*\>0.1 indicated study homogeneity. Therapeutic effects were mainly represented by HRs and ORs presented with 95% CIs. HRs were collected for survival data. If HRs can neither be collected directly nor calculated, survival curve plots were extracted by Engauge Digitizer software and then transformed by specialized form.[@b45-dddt-13-183]--[@b47-dddt-13-183]

Pooled analysis with publication bias determined that the trim-and-fill method would be applied to coordinate the estimates of unpublished studies, and the adjusted results were compared with the original pooled OR.[@b48-dddt-13-183] Sensitivity analysis (subgroup analyses) was conducted to evaluate the impact of different cancer types, SC/B6 dosages, therapeutic regimens, sample sizes, and study types on clinical efficacy.

A total of 974 articles were identified with the initial search, and 602 papers were excluded due to duplication. After title and abstract review, 269 articles were further excluded because they did not include clinical trials (n=209), were reviews or meta-analyses (n=6), were unrelated studies (n=43), or were case reports (n=11), leaving 103 studies as potentially relevant. After detailed assessment of full texts, articles without a control group (n=11), studies with inappropriate criteria in the experimental or control group (n=16), studies with insufficient data (n=5), and studies including patients with non-digestive system tumors (n=47) were excluded. Finally, data from 24 trials[@b8-dddt-13-183],[@b19-dddt-13-183]--[@b41-dddt-13-183] (gastric cancer, n=7; colorectal cancer, n=5; gastrointestinal cancer, n=3; liver cancer, n=7; esophageal cancer, n=1; and pancreatic cancer, n=1) including 1,825 advanced DSN patients were included in the present analysis ([Figure 1](#f1-dddt-13-183){ref-type="fig"}).

Patient characteristics
-----------------------

All studies involved in this analysis were carried out in different hospitals in China. These trials include 1,825 patients with advanced DSNs; of these, 933 were treated by combined SC/B6 and CMT, and 892 were treated by CMT alone. Detailed information on the included trials and patients is presented in [Tables 1](#t1-dddt-13-183){ref-type="table"} and [2](#t2-dddt-13-183){ref-type="table"}.

Quality assessment
------------------

The evaluation of bias risk is presented in [Figure 2](#f2-dddt-13-183){ref-type="fig"}. Twenty-two studies had low risk, and the other two articles did not have a clear description of the randomization process. None of the included trials provided a clear description of the performance and detection risks. Two studies were regarded as high-risk due to the absence of follow-up and seven trials were considered as unclear risk owing to selective reporting.

Therapeutic efficacy assessments
--------------------------------

As shown in [Figures 3](#f3-dddt-13-183){ref-type="fig"} and [4](#f4-dddt-13-183){ref-type="fig"}, [Table 3](#t3-dddt-13-183){ref-type="table"}, and [Figure S1](#SD1-dddt-13-183){ref-type="supplementary-material"}, patients who underwent combined therapy had a significantly improved CR rate (OR =2.06, 95% CI =1.41--3.00, *P*=0.0002), PR rate (OR =1.85, 95% CI =1.50--2.29, *P*\<0.00001), ORR (OR =2.25, 95% CI =1.83--2.76, *P*\<0.00001), and DCR (OR =2.41, 95% CI =1.85--3.15, *P*\<0.00001), and significantly decreased SD and PD rates (SD, OR =0.77, 95% CI =0.63--0.93, *P*=0.009; PD, OR =0.45, 95% CI =0.35--0.59, *P*\<0.00001) compared to patients receiving CMT alone. The OS rates of patients who received combination treatment (HR =0.74, 95% CI =0.47--1.17, *P*=0.20) did not differ significantly from those in patients who received CMT alone.

QoL assessment
--------------

QoL evaluation demonstrated that SC/B6 and CMT combined therapy-treated DSN patients had improved QoL compared to those treated by CMT alone ([Figure 5A](#f5-dddt-13-183){ref-type="fig"}, OR =2.75, 95% CI =2.13--3.55, *P*\<0.00001).

Adverse events assessment
-------------------------

As shown in [Table 4](#t4-dddt-13-183){ref-type="table"} and [Figure S2](#SD2-dddt-13-183){ref-type="supplementary-material"}, patients treated by SC/B6 and CMT combined therapy had lower incidences of leukopenia, nausea and vomiting, gastrointestinal side effects, hepatotoxicity, diarrhea, transaminase disorder, myelosuppression, anorexia, and anemia than those treated with CMT alone (leukopenia: OR =0.29, 95% CI =0.21--0.39, *P*\<0.00001; nausea and vomiting: OR =0.30, 95% CI =0.22--0.40, *P*\<0.00001; gastrointestinal side effects: OR =0.42, 95% CI =0.29--0.62, *P*\<0.00001; hepatotoxicity: OR =0.49, 95% CI =0.30--0.78, *P*=0.003; diarrhea: OR =0.37, 95% CI =0.23--0.60, *P*\<0.0001; transaminase disorder: OR =0.23, 95% CI =0.09--0.62, *P*=0.003; myelosuppression: OR =0.33, 95% CI =0.18--0.60, *P*=0.0003; anorexia: OR =0.37, 95% CI =0.20--0.68, *P*=0.001; anemia: OR =0.54, 95% CI =0.32--0.91, *P*=0.02). No significant difference was found in the occurrence of nephrotoxicity, thrombocytopenia, hand-foot syndrome, and oral mucositis (nephrotoxicity: OR =0.70, 95% CI =0.38--1.30, *P*=0.26; thrombocytopenia: OR =0.77, 95% CI =0.31--1.92, *P*=0.57; hand-foot syndrome: OR =0.75, 95% CI =0.40--1.40, *P*=0.36; oral mucositis: OR =0.45, 95% CI =0.13--1.62, *P*=0.22) between patients receiving combination treatment and those receiving CMT alone.

Publication bias
----------------

Publication bias of primary outcomes (CR, PR, SD, PD, ORR, DCR, QIR, and adverse events) was evaluated and presented by funnel plots. All plots were approximately symmetrical, indicating generally controlled publication bias ([Figures 6](#f6-dddt-13-183){ref-type="fig"} and [S3](#SD3-dddt-13-183){ref-type="supplementary-material"}).

We also assessed the publication bias by Begg's and Egger's regression asymmetry tests, and SD and leukopenia were found to have bias (SD, Egger: 0.024, Begg: 0.039; leukopenia, Egger: 0.041, Begg: 0.080; [Table 5](#t5-dddt-13-183){ref-type="table"}). To determine whether the bias affected the pooled risk, we conducted trim-and-fill analysis. The adjusted OR indicated the same trend as the primary analysis (SD, before: *P*=0.010, after: *P*\<0.0001; leukopenia, before: *P*\<0.0001, after: *P*\<0.0001), reflecting the reliability of our primary conclusions, except those based on a small number of trials.

Sensitivity analysis
--------------------

Subgroup analysis was performed for ORR and DCR heterogeneity assessment concerning cancer types, SC/B6 dosages, therapeutic regimens, sample sizes, and study types of involved trials. No significant difference was observed in the sample sizes, study types, or SC/B6 dosages ([Table 6](#t6-dddt-13-183){ref-type="table"}). SC/B6 combined with CMT was more effective in treating gastric cancer, colorectal cancer, and liver cancer. Moreover, SC/B6 combined with oxaliplatin and capecitabine (XELOX) or capecitabine regimens was more effective for DSN treatment.

Discussion
==========

The chemotherapeutic regimens commonly used to treat DSNs cause serious side effects, such as myelosuppression, hepatotoxicity, and gastrointestinal side effects, which severely affect the QoL of DSN patients.[@b7-dddt-13-183],[@b9-dddt-13-183] Therefore, seeking a therapy that can improve treatment outcomes and decrease the adverse effects of chemotherapy is a major direction in the development of tumor treatment. Traditional Chinese medicine plays a unique role in improving host immunity and lowering the toxic effects of chemotherapy.[@b7-dddt-13-183],[@b9-dddt-13-183],[@b49-dddt-13-183]--[@b52-dddt-13-183] In recent decades, SC/B6 has been clinically applied as an adjuvant therapy for malignancies and has been beneficial for advanced DSN patients in several trials.[@b7-dddt-13-183]--[@b9-dddt-13-183],[@b11-dddt-13-183] Despite the published reports on clinical trials using SC/B6, its therapeutic effects have not been systematically demonstrated. In the present study, we performed an extensive literature search followed by rigorous contrasting and combining data analysis for categorization to provide clear and systematic conclusions.

Our meta-analysis revealed that SC/B6 and CMT combined therapy for DSN patients achieved more beneficial effects than CMT alone. Combined therapy-treated patients exhibited markedly improved ORR and DCR (*P*\<0.05 for all) and also significantly improved QoL. These results indicated that intravenous infusion of SC/B6 improved the curative effects of CMT for advanced DSNs.

Our analysis indicates that most of the adverse events caused by chemotherapy, including leukopenia, nausea and vomiting, gastrointestinal side effects, and hepatotoxicity, were alleviated with SC/B6 combination therapy (*P*\<0.05). Therefore, SC/B6 is a safe auxiliary antitumor medicine for DSN and can effectively alleviate the adverse events associated with chemotherapy.

The analysis of therapeutic effects may be influenced by several factors. In our study, no difference was found between sample sizes, study types, and SC/B6 dosages. SC/B6 combined with CMT was more effective in treating gastric cancer, colorectal cancer, and liver cancer than it was in treating esophageal cancer and pancreatic cancer. Moreover, our subgroup analysis showed that SC/B6 combined with XELOX/capecitabine was more effective for DSN treatment. However, recent studies on the impact of these factors on the curative effect of SC/B6 adjuvant therapy remain insufficient, and further investigations should be performed.

There are some limitations in our analysis. First, the follow-up durations of the included studies were not long enough. Second, as a traditional medicine, SC/B6 was mainly applied in China, which may bring an unavoidable regional bias and subsequently influence the clinical application of SC/B6 worldwide. Furthermore, treatment/medical history is very important for evaluating the efficacy of SC/B6-mediated therapy. However, our data were extracted from published papers rather than from the original patient records; therefore, analytical bias may possibly exist. More original data would be valuable to achieve a higher reliability of statistical analysis on SC/B6 for DSN treatment.

In summary, this meta-analysis indicated that SC/B6 and CMT combined therapy was effective in treating advanced DSNs. Intravenous infusion of SC/B6 not only greatly improved the therapeutic effects of CMT but also effectively alleviated the toxicity and most of the side effects associated with chemotherapy. Therefore, SC/B6 has potential for development as a new adjuvant therapy for the treatment of DSN.

Supplementary materials
=======================

###### 

Forest plot of the comparison of complete response rates (**A**), partial response rates (**B**), stable disease rates (**C**), and progressive disease rates (**D**) between the experimental and control groups. Control group, CMT alone group; Experimental group, sodium cantharidinate and vitamin B6 injection (SC/B6) + CMT. The fixed-effects meta-analysis model (M--H method) was used.

**Abbreviations:** CMT, conventional medical treatment; M--H, Mantel--Haenszel.

###### 

Forest plot of the comparison of adverse effects including leukopenia (**A**), nausea and vomiting (**B**), gastrointestinal side effects (**C**), hepatotoxicity (**D**), nephrotoxicity (**E**), diarrhea (**F**), thrombocytopenia (**G**), transaminase disorder (**H**), myelosuppression (**I**), hand foot syndrome (**J**), oral mucositis (**K**), anorexia (**L**), and anemia (**M**) between the experimental and control groups. Control group, CMT-alone group; Experimental group, sodium cantharidinate and vitamin B6 injection (SC/B6) + CMT.

**Abbreviation:** CMT, conventional medical treatment.

###### 

Funnel plot of percentage of complete response rates (**A**), partial response rates (**B**), stable disease rates (**C**), and progressive disease rates (**D**).
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![Flow diagram of the selection process.](dddt-13-183Fig1){#f1-dddt-13-183}

![Risk of bias summary: review of authors' judgments about each risk of bias item for included studies.\
**Note:** Each color represents a different level of bias: red for high risk, green for low risk, and yellow for unclear risk of bias.](dddt-13-183Fig2){#f2-dddt-13-183}

![Forest plot of the comparison of overall survival between the experimental and control groups.\
**Notes:** Control group, CMT-alone group; Experimental group, sodium cantharidinate and vitamin B6 injection (SC/B6) + CMT. The fixed-effects meta-analysis model (inverse variance method) was used.\
**Abbreviations:** CMT, conventional medical treatment; IV, intravenous.](dddt-13-183Fig3){#f3-dddt-13-183}

###### 

Forest plot of the comparison of overall response rate (**A**) and disease control rate (**B**) between the experimental and control groups.

**Notes:** Control group, CMT-alone group; Experimental group, sodium cantharidinate and vitamin B6 injection (SC/B6) + CMT. The fixed-effects meta-analysis model (M--H method) was used.

**Abbreviations:** CMT, conventional medical treatment; M--H, Mantel--Haenszel.

![](dddt-13-183Fig4)

![](dddt-13-183Fig4a)

![Forest plot of the comparison of quality-of-life improved rate between the experimental and control groups.\
**Notes:** Control group, CMT-alone group; Experimental group, SC/B6 + CMT. The fixed-effects meta-analysis model (M--H method) was used.\
**Abbreviations:** CMT, conventional medical treatment; M--H, Mantel--Haenszel; SC/B6, sodium cantharidinate and vitamin B6 injection.](dddt-13-183Fig5){#f5-dddt-13-183}

![Funnel plot of percentage of overall response rate (**A**), disease control rate (**B**), quality-of-life improved rate (**C**), leukopenia (**D**), nausea and vomiting (**E**), gastrointestinal side effects (**F**), and hepatotoxicity (**G**).\
**Note:** Parameters discussed in over eight papers were conducted bias analyses.](dddt-13-183Fig6){#f6-dddt-13-183}

###### 

Clinical information from the eligible trials in the meta-analysis

  Included studies                  Nation   KPS            Patients Con/Exp   Age (years)          Parameter types      
  --------------------------------- -------- -------------- ------------------ -------------------- -------------------- -------------------
  Chen Y 2016[@b19-dddt-13-183]     China    ND             25/25              61.27±1.46 (mean)    61.25±1.44 (mean)    ORR, DCR, QIR, AE
  Fan LJ 2009[@b20-dddt-13-183]     China    KPS \$60       42/42              51.5 (mean)          52.3 (mean)          ORR, DCR
  Fan QL 2013[@b21-dddt-13-183]     China    KPS \>60       19/23              ND                   ND                   ORR, DCR, QIR, AE
  Fang XH 2016[@b22-dddt-13-183]    China    KPS \>50       37/37              64.3±10.3 (mean)     66.3±9.3 (mean)      ORR, DCR
  Guan LY 2015[@b23-dddt-13-183]    China    KPS \>60       27/27              ND                   ND                   ORR, DCR, QIR, AE
  Jia JM 2013[@b24-dddt-13-183]     China    KPS \$60       18/18              ND                   ND                   ORR, DCR, QIR, AE
  Li GP 2010[@b25-dddt-13-183]      China    KPS \>60       25/25              40--58               42--65               AE
  Liu GW 2017[@b26-dddt-13-183]     China    KPS \$60       20/20              35--76 (mean)        37--74 (mean)        ORR, DCR, QIR, AE
  Liu SH 2008[@b27-dddt-13-183]     China    60--90 (KPS)   32/32              54.7 (mean)          52.2 (mean)          ORR, DCR, QIR, AE
  Mao WD 2016[@b28-dddt-13-183]     China    KPS \$70       32/33              56.3±15.5 (mean)     55.7±17.2 (mean)     ORR, DCR, AE
  Shao H 2014[@b8-dddt-13-183]      China    ND             41/63              41.71±8.55 (mean)    38.74±11.06 (mean)   ORR, DCR
  Shi XY 2017[@b29-dddt-13-183]     China    KPS \>60       48/48              62.14±11.23 (mean)   61.59±11.02 (mean)   ORR, DCR, QIR, AE
  Tian XL 2006[@b30-dddt-13-183]    China    KPS \$70       36/36              52.5±9.6 (mean)      53.4±10.5 (mean)     ORR, DCR, QIR, AE
  Wang JH 2010[@b31-dddt-13-183]    China    50--90 (KPS)   26/26              51.79 (mean)         53.26 (mean)         ORR, DCR, QIR, AE
  Wang YW 2017[@b32-dddt-13-183]    China    KPS \$70       42/42              62.1±10.2 (mean)     61.2±9.7 (mean)      ORR, DCR, QIR, AE
  Wei YF 2015[@b33-dddt-13-183]     China    KPS \>70       44/48              ND                   ND                   ORR, DCR, AE
  Wu ZM 2013[@b34-dddt-13-183]      China    ND             32/32              ND                   ND                   ORR, DCR, AE
  Xie ZX 2016[@b35-dddt-13-183]     China    ND             32/32              58.1±3.2 (mean)      57.3±2.8 (mean)      ORR, DCR, QIR, AE
  You ZY 2015[@b36-dddt-13-183]     China    KPS \$60       85/85              ND                   ND                   ORR, DCR, QIR
  Zeng L 2009[@b37-dddt-13-183]     China    60--80 (KPS)   63/63              ND                   ND                   ORR, DCR, QIR
  Zhang MJ 2011[@b38-dddt-13-183]   China    KPS \$60       38/38              55.0±2.2 (mean)      54.0±2.4 (mean)      ORR, DCR, QIR, AE
  Zhang W 2012[@b39-dddt-13-183]    China    KPS \$70       42/42              61.2 (mean)          62.1 (mean)          ORR, DCR
  Zhang W 2015[@b40-dddt-13-183]    China    KPS \$70       36/48              59.6 (median)        54.2 (median)        ORR, DCR, QIR, AE
  Zhu WQ 2014[@b41-dddt-13-183]     China    ND             50/48              ND                   ND                   ORR, DCR, AE

**Abbreviations:** AE, adverse events; CMT, conventional medical treatment; Con, control group (CMT alone group); DCR, disease control rate; Exp, experimental group (SC/B6 plus CMT combined group); KPS, Karnofsky Performance Score; ND, nondetermined; ORR, overall response rate; QIR, quality-of-life improved rate; SC/B6, sodium cantharidinate and vitamin B6 injection.

###### 

Information of SC/B6 combined with conventional medical treatment

  Included studies                  Therapeutic regimen   Enrollment period                             Dosage of apatinib   
  --------------------------------- --------------------- --------------------------------------------- -------------------- -----------------------------------------------
  Chen Y 2016[@b19-dddt-13-183]     CMT + SC/B6           CMT (raltitrexed, oxaliplatin)                2,013.4--2,016.4     30 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Fan LJ 2009[@b20-dddt-13-183]     CMT + SC/B6           CMT (calcium folinate, 5-Fu)                  2,005.2--2,009.7     30 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Fan QL 2013[@b21-dddt-13-183]     CMT + SC/B6           CMT (S-1)                                     ND                   20 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Fang XH 2016[@b22-dddt-13-183]    CMT + SC/B6           CMT (ND)                                      2,012.1--2,014.8     40 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Guan LY 2015[@b23-dddt-13-183]    CMT + SC/B6           CMT (S-1)                                     2,012.10--2,014.10   50 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Jia JM 2013[@b24-dddt-13-183]     CMT + SC/B6           CMT (oxaliplatin, paclitaxel)                 2,011.1--2,012.10    20 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Li GP 2010[@b25-dddt-13-183]      CMT + SC/B6           CMT (FOLFOX4)                                 2,008.3--2,009.9     40 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Liu GW 2017[@b26-dddt-13-183]     CMT + SC/B6           CMT (capecitabine)                            2,014.1--2,016.1     40 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Liu SH 2008[@b27-dddt-13-183]     CMT + SC/B6           CMT (leucovorin, oxaliplatin)                 2,005.1--2,007.1     30 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Mao WD 2016[@b28-dddt-13-183]     CMT + SC/B6           CMT (capecitabine)                            2,012.6--2,013.12    30 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Shao H 2014[@b8-dddt-13-183]      CMT + SC/B6           CMT (ND)                                      2,011.1--2,012.11    50 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Shi XY 2017[@b29-dddt-13-183]     CMT + SC/B6           CMT (XELOX)                                   2,013.12--2,015.12   20 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Tian XL 2006[@b30-dddt-13-183]    CMT + SC/B6           CMT (mitomycin, adriamycin/5-Fu, cisplatin)   2,001.9--2,003.9     50 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Wang JH 2010[@b31-dddt-13-183]    CMT + SC/B6           CMT (FOLFOX4)                                 2,008.1--2,009.10    50 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Wang YW 2017[@b32-dddt-13-183]    CMT + SC/B6           CMT (capecitabine)                            2,016.6--2,017.6     20 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Wei YF 2015[@b33-dddt-13-183]     CMT + SC/B6           CMT (5-Fu, epirubicin, mitomycin)             2,010.1--2,011.9     80 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Wu ZM 2013[@b34-dddt-13-183]      CMT + SC/B6           CMT (FOLFIRI)                                 2,008.5--2,011.1     50 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Xie ZX 2016[@b35-dddt-13-183]     CMT + SC/B6           CMT (oxaliplatin, S-1)                        2,013.4--2,015.4     40 mL/time (0.1 mg/10 mL, IV), 1 time/day
  You ZY 2015[@b36-dddt-13-183]     CMT + SC/B6           CMT (cisplatin, 5-Fu)                         2,010.4--2,012.6     ND
  Zeng Li 2009[@b37-dddt-13-183]    CMT + SC/B6           CMT (ND)                                      2,005.3--2,008.6     30--50 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Zhang MJ 2011[@b38-dddt-13-183]   CMT + SC/B6           CMT (mitomycin, adriamycin)                   ND                   50 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Zhang W 2012[@b39-dddt-13-183]    CMT + SC/B6           CMT (capecitabine)                            2,007.2--2,011.7     30 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Zhang W 2015[@b40-dddt-13-183]    CMT + SC/B6           CMT (XELOX)                                   2,012.3--2,014.12    30 mL/time (0.1 mg/10 mL, IV), 1 time/day
  Zhu WQ 2014[@b41-dddt-13-183]     CMT + SC/B6           CMT (ND)                                      2,008.3--2,012.3     50 mL/time (0.1 mg/10 mL, IV), 1 time/day

**Abbreviations:** 5-Fu, 5-fluorouracil; CMT, conventional medical treatment; Con, control group (CMT alone group); Exp, experimental group (SC/B6 plus CMT combined group); FOLFOX, oxaliplatin + calcium folinate + 5-fluorouracil; FOLFIRI, calcium folinate + irinotecan + 5-fluorouracil; IV, intravenous; S-1, gimeracil and oteracil porassium capsules; ND, nondetermined; SC/B6, sodium cantharidinate and vitamin B6 injection; XELOX, oxaliplatin + capecitabine.

###### 

Comparison of CR, PR, SD, PD, ORR, and DCR between the SC/B6 + CMT and SC/B6 group

  Parameter   SC/B6 + CMT group   CMT group   Analysis method   Heterogeneity   OR     95% CI   *P*-value    
  ----------- ------------------- ----------- ----------------- --------------- ------ -------- ------------ -----------
  CR          889                 840         Fixed             0               0.99   2.06     1.41--3.00   0.0002
  PR          889                 840         Fixed             0               0.89   1.85     1.50--2.29   \<0.00001
  SD          889                 840         Fixed             43              0.01   0.77     0.63--0.93   0.009
  PD          889                 840         Fixed             0               0.91   0.45     0.35--0.59   \<0.00001
  ORR         889                 840         Fixed             0               0.56   2.25     1.83--2.76   \<0.00001
  DCR         889                 840         Fixed             0               0.93   2.41     1.85--3.15   \<0.00001

**Abbreviations:** CMT, conventional medical treatment; CR, complete response rates; DCR, disease control rate; ORR, overall response rate; PD, progressive disease rates; PR, partial response rates; SC/B6, sodium cantharidinate and vitamin B6 injection; SD, stable disease rates.

###### 

Comparison of adverse events between the SC/B6 + CMT and SC/B6 group

  Adverse events                           SC/B6 + CMT group   CMT group   Analysis method   Heterogeneity    OR      95% CI       *P*-value    
  ---------------------------------------- ------------------- ----------- ----------------- ---------------- ------- ------------ ------------ -----------
  **Leucopenia**                           449                 427         Fixed             0                0.72    0.29         0.21--0.39   \<0.00001
  Leucopenia I + II                        364                 344         Fixed             0                0.92    0.39         0.28--0.54   \<0.00001
  Leucopenia III + IV                      399                 377         Fixed             0                0.99    0.36         0.21--0.63   0.0003
  **Nausea, vomiting**                     407                 393         Fixed             0                0.93    0.30         0.22--0.40   \<0.00001
  Nausea, vomiting I + II                  242                 226         Fixed             0                0.97    0.28         0.19--0.43   \<0.00001
  Nausea, vomiting III + IV                242                 226         Fixed             0                1.00    0.59         0.23--1.51   0.27
  **Gastrointestinal side effects**        278                 271         Fixed             0                0.97    0.42         0.29--0.62   \<0.00001
  Gastrointestinal side effects I + II     167                 162         Fixed             0                0.81    0.49         0.30--0.80   0.004
  Gastrointestinal side effects III + IV   190                 182         Fixed             0                0.54    0.37         0.17--0.79   0.01
  **Hepatotoxicity**                       262                 257         Fixed             0                0.67    0.49         0.30--0.78   0.003
  Hypertension I + II                      206                 201         Fixed             0                0.69    0.54         0.31--0.94   0.03
  Hypertension III + IV                    206                 201         Fixed             0                0.79    0.44         0.12--1.61   0.22
  **Nephrotoxicity**                       277                 272         Fixed             0                0.95    0.70         0.38--1.30   0.26
  Nephrotoxicity I + II                    154                 149         Fixed             0                1.00    0.89         0.39--2.08   0.80
  Nephrotoxicity III + IV                  154                 149         Fixed             Not applicable   1.00    0.14--7.40   1.00         
  **Diarrhea**                             192                 176         Fixed             0                0.61    0.37         0.23--0.60   \<0.0001
  Diarrhea I + II                          192                 176         Fixed             0                0.74    0.38         0.23--0.62   \<0.0001
  Diarrhea III + IV                        192                 176         Fixed             0                0.81    0.58         0.15--2.30   0.44
  **Thrombocytopenia**                     143                 169         Random            63               0.03    0.77         0.31--1.92   0.57
  Thrombocytopenia I + II                  141                 137         Fixed             0                0.69    0.50         0.27--0.92   0.03
  Thrombocytopenia III + IV                141                 137         Fixed             0                0.98    0.43         0.09--1.95   0.27
  **Transaminase disorder**                149                 145         Random            55               0.07    0.23         0.09--0.62   0.003
  Transaminase disorder I + II             117                 113         Fixed             0                0.40    0.33         0.15--0.69   0.004
  Transaminase disorder III + IV           117                 113         Fixed             0                0.80    0.46         0.08--2.57   0.38
  **Myelosuppression**                     151                 152         Fixed             0                0.90    0.33         0.18--0.60   0.0003
  Myelosuppression I + II                  151                 152         Random            79               0.003   0.70         0.23--2.08   0.52
  Myelosuppression III + IV                113                 114         Random            0                0.81    0.28         0.11--0.73   0.009
  **Hand-foot syndrome**                   116                 104         Fixed             0                0.39    0.75         0.40--1.40   0.36
  Hand-foot syndrome I + II                116                 104         Fixed             0                0.70    0.83         0.44--1.57   0.56
  Hand-foot syndrome III + IV              116                 104         Fixed             0                0.51    0.49         0.10--2.41   0.38
  **Oral mucositis**                       45                  45          Fixed             0                0.98    0.45         0.13--1.62   0.22
  Oral mucositis I + II                    45                  45          Fixed             0                0.63    0.34         0.07--1.59   0.17
  Oral mucositis III + IV                  45                  45          Fixed             Not applicable   1.00    0.13--7.72   1.00         
  **Anorexia**                             92                  88          Fixed             39               0.20    0.37         0.20--0.68   0.001
  Anorexia I + II                          92                  88          Fixed             39               0.20    0.37         0.20--0.68   0.001
  Anorexia III + IV                        92                  88          Fixed             Not applicable                                     
  **Anemia**                               162                 162         Fixed             0                0.73    0.54         0.32--0.91   0.02
  Anemia I + II                            77                  77          Fixed             0                0.49    0.60         0.31--1.16   0.13
  Anemia III + IV                          77                  77          Fixed             0                0.84    0.41         0.06--2.90   0.37

**Abbreviations:** CMT, conventional medical treatment; SC/B6, sodium cantharidinate and vitamin B6 injection.

###### 

Publication bias on therapeutic efficacy and adverse events

  Publication bias   Therapeutic efficacy   Adverse events                                                                   
  ------------------ ---------------------- ---------------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  Begg               0.058                  0.154            0.039   0.195   0.369   0.612   1.000   0.080   0.213   0.386   0.711
  Egger              0.078                  0.259            0.024   0.149   0.489   0.425   0.808   0.041   0.697   0.198   0.581

**Note:** Parameters discussed in over eight papers were conducted bias analyses.

**Abbreviations:** CR, complete response rates; DCR, disease control rate; ORR, overall response rate; PD, progressive disease rates; PR, partial response rates; QIR, quality-of-life improved rate; SD, stable disease rates.

###### 

Subgroup analyses of ORR and DCR between the SC/B6 + CMT and SC/B6 groups

  Parameter                    Factors at study level   Exp group   Con group   Analysis method   Heterogeneity   OR      95% CI         *P*-value
  ---------------------------- ------------------------ ----------- ----------- ----------------- --------------- ------- -------------- -----------
  ORR                          **Type of cancer**                                                                                        
  Gastric cancer               219                      206         Fixed       0                 0.60            1.78    1.20--2.66     0.005
  Colorectal cancer            161                      161         Fixed       0                 0.79            2.60    1.59--4.26     0.0001
  Gastrointestinal cancer      150                      146         Fixed       0                 0.96            2.48    1.53--4.02     0.0002
  Liver cancer                 314                      282         Fixed       54                0.04            2.42    1.70--3.43     \<0.00001
  Esophageal cancer            18                       18          Fixed                                         2.00    0.52--7.69     0.31
  Pancreatic cancer            27                       27          Fixed                                         1.56    0.24--10.19    0.64
  **Dosage of SC/B6**                                                                                                                    
  20 mL/day                    131                      127         Fixed       0                 0.93            2.16    1.28--3.66     0.004
  30 mL/day                    222                      209         Fixed       0                 0.81            2.37    1.56--3.58     \<0.0001
  40 mL/day                    89                       89          Fixed       0                 0.61            2.19    1.17--4.09     0.01
  50 mL/day                    251                      223         Fixed       0                 0.54            1.68    1.12--2.52     0.01
  **Therapeutic regimen**                                                                                                                
  SC/B6 + XELOX                96                       84          Fixed       0                 0.96            1.83    0.97--3.45     0.06
  SC/B6 + S-1                  50                       46          Fixed       0                 0.76            2.00    0.71--5.63     0.19
  SC/B6 + capecitabine         137                      136         Fixed       0                 0.94            2.91    1.70--4.97     \<0.0001
  **Study sample size**                                                                                                                  
  \<80                         511                      469         Fixed       10                0.35            2.70    2.04--3.57     \<0.00001
  \>80                         378                      371         Fixed       0                 0.84            1.80    1.32--2.44     0.0002
  **Type of control trials**                                                                                                             
  RCT                          816                      767         Fixed       0                 0.50            2.24    1.81--2.78     \<0.00001
  Overall                      889                      840         Fixed       0                 0.56            2.25    1.83--2.76     \<0.00001
  DCR                          **Type of cancer**                                                                                        
  Gastric cancer               219                      206         Fixed       0                 0.67            2.32    1.43--3.76     0.0006
  Colorectal cancer            161                      161         Fixed       0                 0.91            2.41    1.37--4.26     0.002
  Gastrointestinal cancer      150                      146         Fixed       0                 0.61            2.32    0.90--6.02     0.08
  Liver cancer                 314                      282         Fixed       0                 0.69            2.65    1.64--4.27     \<0.0001
  Esophageal cancer            18                       18          Fixed                                         10.82   1.17--100.44   0.04
  Pancreatic cancer            27                       27          Fixed                                         1.16    0.40--3.43     0.78
  **Dosage of SC/B6**                                                                                                                    
  20 mL/day                    131                      127         Fixed       0                 0.59            2.87    1.54--5.35     0.0009
  30 mL/day                    222                      209         Fixed       0                 0.79            2.39    1.45--3.93     0.0006
  40 mL/day                    89                       89          Fixed       46                0.17            2.22    0.91--5.45     0.08
  50 mL/day                    251                      223         Fixed       0                 0.55            2.45    1.53--3.93     0.0002
  **Therapeutic regimen**                                                                                                                
  SC/B6 + XELOX                96                       84          Fixed       0                 0.39            2.76    1.48--5.14     0.001
  SC/B6 + S-1                  50                       46          Fixed       18                0.27            1.63    0.66--4.01     0.29
  SC/B6 + capecitabine         137                      136         Fixed       0                 0.88            2.08    0.97--4.45     0.06
  **Study sample size**                                                                                                                  
  \>80                         511                      469         Fixed       0                 0.97            2.40    1.64--3.51     \<0.00001
  \<80                         378                      371         Fixed       0                 0.59            2.42    1.67--3.52     \<0.00001
  **Type of control trials**                                                                                                             
  RCT                          816                      767         Fixed       0                 0.89            2.40    1.80--3.20     \<0.00001
  Overall                      889                      840         Fixed       0                 0.93            2.41    1.85--3.15     \<0.00001

**Abbreviations:** CMT, conventional medical treatment; Con, control group (CMT alone group); DCR, disease control rate; Exp, experimental group (SC/B6 plus CMT combined group); RCT, randomized controlled trial; ORR, overall response rate; S-1, gimeracil and oteracil porassium capsules; SC/B6, sodium cantharidinate and vitamin B6 injection; XELOX, oxaliplatin + capecitabine.
